View the 50 largest pharmaceutical companies in the world listings here
STADA Arzneimittel
Rank: 41
2024 Revenues ($USD) : $4.04B
STADA reported strong financial results for 2024, with group sales increasing by 9% to €4.059B. Adjusted EBITDA rose by 11% to €886M, with an improved margin of 21.8%. The company demonstrated growth across all three business segments, with Consumer Healthcare reaching €1.537B, Generics €1.652B, and Specialty Pharmaceuticals €870M (the fastest-growing segment). STADA has targeted further sales and profit growth for 2025 while making significant progress in sustainability initiatives.